10x Genomics, Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
TXG$65.05+9.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $473,966 | $344,067 |
| Marketable securities | 49,443 | 49,335 |
| Accounts receivable, net | 47,013 | 87,862 |
| Inventory | 56,341 | 83,107 |
| Other receivables | 35,480 | 606 |
| Prepaid expenses and other current assets | 22,208 | 19,410 |
| Total current assets | 684,451 | 584,387 |
| Property and equipment, net | 226,711 | 252,648 |
| Operating lease right-of-use assets | 60,450 | 57,290 |
| Goodwill | 4,511 | 4,511 |
| Intangible assets, net | 62,329 | 15,671 |
| Other noncurrent assets | 2,913 | 4,129 |
| Total assets | $1,041,365 | $918,636 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $12,733 | $12,909 |
| Accrued compensation and related benefits | 42,500 | 33,615 |
| Accrued expenses and other current liabilities | 39,971 | 41,165 |
| Deferred revenue | 23,902 | 20,658 |
| Operating lease liabilities | 10,985 | 9,286 |
| Contingent consideration, current | 23,363 | — |
| Total current liabilities | 153,454 | 117,633 |
| Contingent consideration, noncurrent | 1,237 | — |
| Operating lease liabilities, noncurrent | 73,376 | 73,327 |
| Deferred revenue, noncurrent | 10,501 | 12,513 |
| Other noncurrent liabilities | 6,471 | 5,029 |
| Total liabilities | 245,039 | 208,502 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 127,691,329 (Class A 117,612,457, Class B 10,078,872) and 122,291,837 (Class A 108,235,004, Class B 14,056,833) shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2 | 2 |
| Additional paid-in capital | 2,306,690 | 2,177,672 |
| Accumulated deficit | (1,510,591) | (1,467,047) |
| Accumulated other comprehensive income (loss) | 225 | (493) |
| Total stockholders’ equity | 796,326 | 710,134 |
| Total liabilities and stockholders’ equity | $1,041,365 | $918,636 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.